Opus Genetics is trading 7.46% up at $3.89, with gains possibly reflecting speculative positioning ahead of clinical data, though no fresh company-specific announcement was identified for September 1, 2026.
- Previously announced catalyst remains three-month OPGx-BEST1 Cohort 1 data expected during the second week of September 2026.
- Broader markets are modestly lower, so macro sentiment does not clearly explain the stock’s gains; the speculative positioning connection remains unconfirmed.